Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buprenorphine (Indivior, 1bfcb6)
- Development stage
- Unknown
- Lead developer
- Indivior
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Buprenorphine (specifically the Sublocade formulation by Indivior) is an extended-release subcutaneous injection indicated for the treatment of moderate-to-severe opioid use disorder (OUD). It utilizes the ATRIGEL delivery system, which consists of a biodegradable poly (DL-lactide-co-glycolide) polymer dissolved in a biocompatible solvent that solidifies upon contact with body fluids to form a solid depot. This depot subsequently delivers buprenorphine over a one-month period. Mechanistically, buprenorphine acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. This pharmacological profile helps to reduce opioid cravings and withdrawal symptoms while exhibiting a ceiling effect on respiratory depression, providing a safer alternative to full opioid agonists. It is intended for use as part of a complete treatment program that includes counseling and psychosocial support.
- Brand names
- Sublocade
- Other names
- buprenorphine extended-releasebuprenorphine ERextended-release buprenorphine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin receptor)
Beyond the preview
Go deeper on buprenorphine (Indivior, 1bfcb6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buprenorphine (Indivior, 1bfcb6).